Taysha Gene Therapies, Inc. TSHA 深 滬

Earnings Scheduled For May 6, 2026

Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...

05-07 05:03

Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of $(0.08) per share from

05-06 20:06

Taysha Gene Therapies To Reveal New Preclinical Data Supporting Construct Design Of TSHA-102 For Rett Syndrome At The ASGCT 2026 Annual Meeting

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the

04-28 05:30

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

04-27 21:21

美股牛股 | “网红鞋”公司Allbirds“改卖算力”获资金爆炒，股价狂涨580%；WATT大涨34%

“网红鞋”公司Allbirds“改卖算力”获资金爆炒，股价狂涨580%；WATT大涨34%，与知名大型客户合作扩大，无线充电技术商业化获重大突破>>

04-16 19:16

美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元

今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元

04-07 11:53

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.

04-06 23:16

Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires

Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires Taysha Gene Therapies granted inducement equity awards to four new employees under its 2023 Inducement Plan. Awards included restricted stock units covering 300,000 shares. Stock options covered 92,400 shares with an exercise pric

04-03 20:00

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies granted RSUs and stock options to four new employees, totaling 300,000 shares and 92,400 options, under its 2023 Inducement Plan. The RSUs vest annually over four years, while the options have a $4.31 exercise price and vest over four years, with 25% on the first anniversary and the rest monthly over 36 months. Taysha focuses on AAV-based gene therapies for severe CNS monogenic diseases, with its lead program TSHA-102 target...

04-03 12:00

Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate.

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over losses of $(0.07) per

03-19 20:02